Compare Ginkgo Bioworks Holdings Inc (DNA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Novo Nordisk A/S — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Novo Nordisk A/S trades at $49.2 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 364× Ginkgo Bioworks Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.67% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NVO | |
|---|---|---|
Market Cap | $590.53M | $214.94B |
Sector | Health | Health |
52-Week High | $16.14 | $71.70 |
52-Week Low | $5.48 | $35.29 |
Enterprise Value | $627.78M | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
